Syngene International Management

Management criteria checks 3/4

Syngene International's El consejero delegado es Jonathan Hunt , nombrado en Jan 2016, tiene un mandato de 8.08 años. la remuneración anual total es ₹84.75M , compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente 0.088% de las acciones de la empresa, por valor de ₹260.12M . La antigüedad media del equipo directivo y del consejo de administración es de 7 años y 6.8 años respectivamente.

Key information

Jonathan Hunt

Chief executive officer

₹84.8m

Total compensation

CEO salary percentage	100.0%
CEO tenure	8.3yrs
CEO ownership	0.09%
Management average tenure	7.2yrs
Board average tenure	6.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jonathan Hunt's remuneration changed compared to Syngene International's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹5b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹85m	₹85m	₹5b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹4b
Mar 31 2022	₹76m	₹76m	₹4b
Dec 31 2021	n/a	n/a	₹4b
Sep 30 2021	n/a	n/a	₹4b
Jun 30 2021	n/a	n/a	₹4b
Mar 31 2021	₹65m	₹65m	₹4b
Dec 31 2020	n/a	n/a	₹4b
Sep 30 2020	n/a	n/a	₹4b
Jun 30 2020	n/a	n/a	₹4b
Mar 31 2020	₹66m	₹66m	₹4b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹3b
Mar 31 2019	₹90m	₹47m	₹3b
Dec 31 2018	n/a	n/a	₹3b
Sep 30 2018	n/a	n/a	₹3b
Jun 30 2018	n/a	n/a	₹3b
Mar 31 2018	₹94m	₹47m	₹3b

Compensación vs. Mercado: Jonathan($USD1.02M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD547.70K).

Compensación vs. Ingresos: La compensación de Jonathan ha sido consistente con los resultados de la empresa en el último año.

CEO

Jonathan Hunt (54 yo)

8.3yrs

Tenure

₹84,750,000

Compensation

Mr. Jonathan Brittan Hunt serves as the Managing Director of Syngene International Limited since April 1, 2020. He has been the Chief Executive Officer of Syngene International Ltd. since January 2016 and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jonathan Hunt	MD, CEO & Executive Director	8.3yrs	₹84.75m	0.088% ₹ 253.6m
Sibaji Biswas	CFO & Executive Director	4.3yrs	₹34.14m	0.017% ₹ 49.6m
Krishnan G	Head of Investor Relations	no data	no data	0.0013% ₹ 3.8m
Priyadarshini Mahapatra	Company Secretary & Compliance Officer	4.8yrs	₹4.72m	0.0031% ₹ 9.1m
Sandeep Nair	Head of Corporate Communications	no data	no data	no data
Andrew Webster	Chief Human Resources Officer	1.3yrs	no data	no data
Dhananjay Patankar	Head of Pharmaceutical & Biopharmaceutical Development	no data	₹10.80m	no data
Purushottam Singnurkar	Head of Formulations Development	no data	₹5.50m	0.029% ₹ 84.7m
Ajit Manocha	Head of IT	8.2yrs	no data	0.00038% ₹ 1.1m
Jayashree Aiyar	Head of Discovery Biology	8.3yrs	no data	0.0060% ₹ 17.5m
Chetan Tamhankar	Head of Clinical Development & Stability Studies	8.3yrs	no data	0.0048% ₹ 14.0m
Rajendra Patil	Head of EHSS	6.3yrs	no data	0.0064% ₹ 18.4m

7.2yrs

Average Tenure

Equipo directivo experimentado: 539268El equipo directivo de la empresa es veterano y experimentado (7 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jonathan Hunt	MD, CEO & Executive Director	6.9yrs	₹84.75m	0.088% ₹ 253.6m
Sibaji Biswas	CFO & Executive Director	no data	₹34.14m	0.017% ₹ 49.6m
Catherine Rosenberg	Non-Executive Director	23.7yrs	₹7.25m	0.0022% ₹ 6.4m
Kiran Mazumdar-Shaw	Non-Executive Chairperson	no data	₹8.23m	0.0055% ₹ 16.0m
Vinita Bali	Lead Independent Director	6.8yrs	₹7.57m	no data
Vijay Kuchroo	Independent Director	7.1yrs	₹6.93m	0.013% ₹ 36.5m
Nilanjan Roy	Additional Independent Director	less than a year	no data	no data
Kush Parmar	Independent Non Executive Director	2.8yrs	₹5.61m	no data
Paul Blackburn	Non-Executive Independent Director	9.7yrs	₹7.91m	0.013% ₹ 36.5m
Sharmila Karve	Additional Independent Director	4.7yrs	₹7.57m	no data

6.8yrs

Average Tenure

62yo

Average Age

Junta con experiencia: La junta directiva de 539268 se considera experimentada (6.8 años de antigüedad promedio).

Syngene International Management

Management criteria checks 3/4

Key information

Recent management updates

Head of IT recently sold ₹1.5m worth of stock

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Insider recently sold ₹9.9m worth of stock

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Insider recently sold ₹7.1m worth of stock

Recent updates

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

Head of IT recently sold ₹1.5m worth of stock

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Chief Human Resources Officer recently sold ₹13m worth of stock

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited, Annual General Meeting, Jul 20, 2022

Upcoming dividend of ₹1.00 per share

Syngene International Limited Recommends Special Additional Dividend for the Financial Year Ended March 31, 2022

Insider recently sold ₹1.7m worth of stock

Syngene International Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q4, 2022 Results on Apr 27, 2022

Syngene International Limited Appoints Carl Decicco as Additional Director Non-Executive Non-Independent of the Company

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insider recently sold ₹2.7m worth of stock

Insider recently sold ₹6.3m worth of stock

Second quarter 2022 earnings released: EPS ₹1.64 (vs ₹2.12 in 2Q 2021)

Insider recently sold ₹3.2m worth of stock

Insider recently sold ₹19m worth of stock

Insider recently sold ₹8.8m worth of stock

Insider recently sold ₹5.0m worth of stock

Insider recently sold ₹2.5m worth of stock

Non-Executive Director John Shaw has left the company

Price target increased to ₹673

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹10.18 (vs ₹10.38 in FY 2020)

Insider recently sold ₹1.8m worth of stock

Full year 2021 earnings released: EPS ₹10.18 (vs ₹10.38 in FY 2020)

Insider recently sold ₹2.1m worth of stock

New 90-day low: ₹556

Earnings beat expectations, revenue disappoints